tbuckley/cabot-search huggingface dataset:
Nerve Membrane Ion Channels as the Target Site of Environmental Toxicants
Authors: Toshio Narahashi
Journal: Environmental Health Perspectives (1987)

There are many environmentally important chemicals which exhibit potent effects on the nervous system. Examples include insecticides such as pyrethroids, DDT, cyclodienes, organophosphates and carbamates, and heavy metals such as mercury and lead. Since nerve excitation takes place in a fraction of a second, electrophysiological methods provide us with the most straightforward approach to the study of the mechanisms of action of environmental toxicants on the nervous system. Aquatic animals such as crayfish, lobster, squid, and marine snails represent extremely useful materials for such electrophysiological studies, because much of our knowledge of nerve excitation is derived from those animals. Nerve excitation takes place as a result of opening and closing of ion channels of the membrane. These functions are independent of metabolic energy, and can be measured most effectively by voltage clamp techniques as applied to the giant axons of the crayfish and the squid. Patch clamp techniques developed during the past 10 years have added a new dimension to the electrophysiological investigation. These techniques allow us to measure the activity of individual ion channels, thereby making it possible to analyze the interaction of toxic molecules directly with single ion channels. Examples are given summarizing electrophysiological studies of environmental neurotoxicants. The abdominal nerve cords and neuromuscular preparations isolated from the crayfish are convenient materials for bioassay of certain environmental toxicants such as pyrethroids, chlorinated hydrocarbons, and other insecticides. Detailed voltage clamp and patch clamp analyses have revealed that pyrethroids and DDT modify the sodium channel to remain open for an extended period of time. This change causes an increase in depolarizing afterpotential which reaches the threshold for repetitive discharges to be produced.(ABSTRACT TRUNCATED AT 250 WORDS)
Abstract 1674: Prediction of survival based on tumor size dynamics and new lesions in EGFR mutation-positive non-small cell lung cancer patients treated with gefitinib or carboplatin and paclitaxel
Authors: James Dunyak, Jacqueline Buros-Novik, Eric Novik, Hong Yan, Nidal Al-Huniti
Journal: Cancer Research (2019)

Abstract Objectives: Dynamics of tumor size have long been used for the clinical diagnosis, staging, prognosis and treatment of non-small cell lung cancer (NSCLC). The aim of this work was to develop a joint statistical framework to interrogate the longitudinal tumor burden, the appearance of new lesions, and changes in therapy following progression in a population of NSCLC patients treated with an EGFR inhibitor gefinitib to predict, given early results, time to progression (PFS) and overall survival at both population and individual levels. Methods: The model builds on a previously developed joint model for tumor size and survival. The tumor size model was extended to estimate the probability of a new lesion. For the survival submodel, two additional biomarkers were evaluated: the derivative of the sum of longest diameters (SLD) and the probability of new lesions. The model was fitted in a Bayesian framework using STAN. Model was developed from 434 EGFR+, NSCLC patients treated with gefitinib or carboplatin+paclitaxel (‘IPASS’, NCT00322452). Predictive performance was evaluated on a cohort of 102 EGFR+ NSCLC patients (‘IFUM’, NCT01203917). Results: Overall, the model fit well to the observed data and the predictive performance was strong in both within- and out-of-sample evaluations. Surprisingly, SLD derivative and new-lesion association parameters appear to negatively impact model performance, indicating further improvement of these submodels might be necessary. The model recapitulates response evaluation criteria in solid tumors (RECIST) outcomes with nearly 90% accuracy. When comparing progression-specific hazards, it appears the drug effect is mediated by tumor size dynamics rather than new lesion incidence. Conclusion: This Bayesian joint model of tumor size and survival accurately recapitulates the RECIST-based outcomes and generates well calibrated predictions of survival. It offers insights regarding the relative predictive value of the components of RESICT in NSCLC. Citation Format: James Dunyak, Jacqueline Buros-Novik, Eric Novik, Hong Yan, Nidal Al-Huniti. Prediction of survival based on tumor size dynamics and new lesions in EGFR mutation-positive non-small cell lung cancer patients treated with gefitinib or carboplatin and paclitaxel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1674.
Books Received
Authors: Pedro L. Delgado, Ricardo Cáceda, Nolan C. Kordsmeier, Eric Golden, Hunter M. Gibbs, Wei-Lieh Huang, Shih-Cheng Liao, Henriët van Middendorp, Andrea W.M. Evers, Judith Tekampe, Stefanie H. Meeuwis, Jelle W.R. van Leusden, Gustavo Pacheco-López, Ad R.M.M. Hermus, Harald Gündel, Jian Li, Natalie Riedel, Amira Barrech, Raphael M. Herr, Birgit Aust, Kathrin Mörtl, Johannes Siegrist, Peter Angerer, Franny B. Spengler, Benjamin Becker, Keith M. Kendrick, Rupert Conrad, René Hurlemann, Goetz Schade, Per Bech, Nina Timmerby, Vibeke Nørholm, Niels-Anton Rasmussen, Lone Lindberg, Kate Andreasson Aamund, Hans-Christoph Friederich, Beate Wild, Martina de Zwaan, Stephan Herpertz, Bernd Löwe, Stephan Zipfel, Wolfgang Herzog, Timo Brockmeyer, Gaby Resmark, Andreas Dinkel, Markus Burgmer, Sefik Tagay, Eva Rothermund, Carlos De las Cuevas, Jose de Leon, Joaquim Radua, Heinz Grunze, Benedikt L. Amann, Almut Zeeck, Michael J. Lambert, Eric L. Garland, Matthew O. Howard, Jon-Kar Zubieta, Brett Froeliger, Paolo Leombruni, Ross J. Baldessarini, Alberto Forte, Valerio Selle, Kang Sim, Leonardo Tondo, Juan Undurraga, Gustavo H. Vázquez, Satz Mengensatzproduktion, Druckerei Stückle, Druckerei Stückle
Journal: Psychotherapy and Psychosomatics (2017)
Obstetrics and Gynecology
Authors: Edward C. Hill
Journal: JAMA (1982)

Heightened public interest in medical progress has brought the news media into an ever increasing role in the dissemination of new information. Frequently, the television, radio, or newspaper is the first source of such information, long before it appears in the medical journals, where a careful, dispassionate presentation of the facts can be made and subjected to peer review and criticism. Two developments in obstetrics and gynecology received wide publicity in 1981, exciting the imagination of the medical profession and the lay public. These were the birth of the first baby in the United States to result from in vitro fertilization and embryo transfer, and the successful in utero placement of an indwelling suprapubic bladder catheter into a male fetus with urethral obstruction, allowing further in utero development. Both of these events were the result of tremendous strides in several disciplines and the amalgamation of their findings. Both occurred because
Correction
Journal: BMJ (1951)

3) Is it true that we are now workmen from the point of view of being " proceeded against " and not workmen from the point of view of arbitration ?(4) The B.M.A. is not a trade union and is, therefore, not included in Order No. 1376.Was it omitted by accident or design ?(5) What happens if a dispute arises within this Order ?(Or are we waiting to consider this point until a dispute actually does arise ?)Both these are negative Orders, having the force of law if not annulled within 40 days.There are, therefore, 36 days from the summoning of the new Parliament in which effective action may be taken.Failing effective action, surely withdrawal from the Service is our only alternative.The issue is as important as that in the minds of some of us.What do our leaders think ?Do we not deserve to be told ?-I am, etc.,Winchester.
The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia☆, ☆☆, ★, ★★
Authors: L DRAKE, M HORDINSKY, V FIEDLER, J SWINEHART, W UNGER, P COTTERILL, D THIBOUTOT, N LOWE, C JACOBSON, D WHITING
Journal: Journal of the American Academy of Dermatology (1999)
Medical Masks
Authors: Angel N. Desai, Preeti Mehrotra
Journal: JAMA (2020)

Lisa A. Pompeii, PhD; Colleen S. Kraft, MD, MSc; Erik A. Brownsword, MPP; Morgan A. Lane, MPH; Elisa Benavides, MPH; Janelle Rios, MPH, PhD; Lewis J. Radonovich Jr, MD
Manuscripts Approved for JNCI, May 1 to June 1, 1970
Journal: JNCI Journal of the National Cancer Institute (1970)

Journal Article Manuscripts Approved for JNCI, May 1 to June 1, 1970 Get access JNCI: Journal of the National Cancer Institute, Volume 45, Issue 1, July 1970, Pages 212–213, https://doi.org/10.1093/jnci/45.1.212 Published: 01 July 1970
Endoscopic Ultrasonography
Authors: G Caletti, P Fusaroli
Journal: Endoscopy (1999)

Areas of application for endosonography can be roughly divided into three categories: standard diagnostic examination; operative diagnostic examination (fine-needle aspiration); and operative therapeutic procedures. Nevertheless, endoscopic ultrasonography remains a single technique, in which the physician can not only raise a suspicion of a particular disease, but can also obtain cytological confirmation when needed and carry out a therapeutic procedure when indicated. Widely accepted indications for endosonography are the staging of esophageal and rectal cancer, and the visualization of submucosal lesions and gastric wall diseases; other indications, such as imaging of the pancreas and biliary tree, are still being discussed.
Highlights from this issue
Authors: The Triumvirate
Journal: Thorax (2021)

The TriumvirateMany of the Thorax readership will have been in short trousers when the Rocky Horror Picture Show first hit the screens in 1975.Although panned by the critics on its release, the film has gathered a cult following-with cinema goers dressing as characters from the film and extensive audience participation.The film is still shown in cinemas, making it the longest-running theatrical release in film history (though no match for Thorax which is 75 this year).This month we bring you a "Rocky Horror Airwaves".
Optimal criteria for care of heart disease patients
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CDC ponders new HIV guidelines
Authors: M. F. Goldsmith
Journal: JAMA (1990)

THIS MORNING, officials at the Centers for Disease Control (CDC) can get to work on new<i>Recommendations for Prevention of HIV Transmission in Health-Care Settings</i>. September 4 was the deadline for comments and suggestions that came out of the CDC Consultants' Meeting on Prevention of Transmission of Bloodborne Pathogens to Patients During Invasive Procedures. That meeting, held in Atlanta, Ga, August 13 and 14, followed a<i>Morbidity and Mortality Weekly Report</i>that noted the first "Possible Transmission of Human Immunodeficiency Virus to a Patient during an Invasive Dental Procedure." (See page 1092.) Representatives of medical and dental specialty societies, local and federal government health and regulatory agencies, hospitals, law and ethics groups, labor, academe, the armed services, and others met to review current policies and practices with an eye toward making any needed changes given new knowledge about the acquired immunodeficiency syndrome (AIDS). Concerns about the lack of relevant details
patience
Authors: Clayton J. Baker
Journal: Annals of Internal Medicine (2007)

Ad Libitum20 February 2007patienceClayton J. Baker, MDClayton J. Baker, MDFrom Pittsford, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-146-4-200702200-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail shaken awakeand then askedhow you sleptpunctured and bledto assessfor blood lossdrugged every nightso you won'tgrow confusedas nausea churnslike a spitthrough your gutsomehow you stillcrack a smileand say thanks Author, Article, and Disclosure InformationAffiliations: From Pittsford, New York.Current Author Address: Clayton J. Baker, MD, 1919 Calkins Road, Pittsford, NY 14534. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 February 2007Volume 146, Issue 4Page: 316KeywordsBloodDrugsNausea ePublished: 20 February 2007 Issue Published: 20 February 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Complementary medicine congress draws a crowd
Authors: C. Marwick
Journal: JAMA (1995)

ALTERNATIVE medical practices are edging their way into the US health care system. If anyone remained unaware of this movement (<i>N Engl J Med</i>. 1993;328:246-252 and 282-283), the proceedings at the first International Congress on Alternative and Complementary Medicine, held in Arlington, Va, would have enlightened them. Legislative moves (both federal and state), steps to ensure access to alternative (or complementary or unconventional) medical therapies, and a long list of alternative medical practices including homeopathy, massage, spiritual healing, special diets, relaxation techniques, and more were discussed by nearly 200 speakers during the 4-day conference. The event is a reflection of public interest in the topic. During the first session, it was announced that from now on the congress would be an annual affair. It was organized by Mary Ann Liebert, publisher of the<i>Journal of Alternative and Complementary Medicine</i>and<i>Alternative Complementary Therapies</i>. The first is a peer-reviewed journal edited
The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda
Authors: A Roberts
Journal: Hepatology (1997)

The cause of the hepatic siderosis and iron overload that is common in porphyria cutanea tarda (PCT) is uncertain. Heterozygosity for genetic hemochromatosis has been supported by some studies of the association between the HLA-A3 antigen and porphyria cutanea tarda but not by others. The hemochromatosis gene is now believed to be located telomeric to HLA-A3 and close to the DNA microsatellite marker D6S1260. We have used this and other microsatellite markers, which together define an ancestral haplotype that is strongly linked to hemochromatosis, to reinvestigate the relationship between these disorders in 41 British patients with sporadic PCT. Fifteen patients carried the hemochromatosis-associated alleles D6S265-1 and D6S105-8. Four of these were homozygous for the ancestral haplotype D6S265-1: D6S105-8: D6S1260-4. We estimate that approximately 37% of British patients with sporadic PCT carry at least one hemochromatosis gene compared with 10% of the general population.
Abstract SY17-02: Solid tumor cancer stem cells: From bench to bedside
Authors: Michael F. Clarke
Journal: Cancer Research (2019)

Abstract Stem cells are essential for maintenance of multiple tissues including the intestine, skin, brain and breast. Remarkably, cancers invariably arise in tissues that contain stem cells whose function is to maintain and repair tissues for the life of the animal. Self renewal, the mechanisms by which stem cells regenerate themselves, is the fundamental property by which stem cells maintain themselves. Our laboratory investigates the fundamental molecular mechanisms of self renewal. Our studies have found that stem cells can be identified by the expression of genes required for self renewal AND by the lack of expression of genes that suppress self renewal. The specific components of self renewal pathways in normal and malignant colon and mammary gland stem cells will be discussed. Stem cell pathways contribute to minimal residual disease after cancer therapy will be discussed. Finally, the application of stem cell biology to cancer therapy will be described. Approximately 4-7% of stage 2 colon cancers consist of homogeneous populations of undiffentiated CDX2- cancer cells. Stage 2 colon cancer patients are generally not thought to benefit from adjuvant chemotherapy. However, stage 2 colon cancer patients with CDX 2- cancer do appear to benefit. Citation Format: Michael F. Clarke. Solid tumor cancer stem cells: From bench to bedside [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr SY17-02.
A piece of my mind. Knife and gun clubs of America
Authors: L. J. Purdy
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Labeling of Neurons by Intracellular Injection of Fluorescent Dyes
Authors: Beat H. Gähwiler
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Authors: A. P. Kotsakis, D. E. Heron, G. J. Kubicek, R. L. Ferris, S. Kim, M. K. Gibson, U. Duvvuri, J. R. Grandis, J. T. Johnson, A. Argiris
Journal: Journal of Clinical Oncology (2010)

TPS264 Background: RT and E, an anti-EGFR monoclonal antibody, has emerged as a standard nonsurgical therapy for stage III/IV SCCHN. Pem, a multitargeted antifolate that inhibits several enzymes of the folate pathway (thymidylate synthetase, dihydrofolate reductase, and other) has attributed promising results in SCCHN. We previously established the recommend doses of Pem in combination with RT plus E in SCCHN (ASCO 2008; A2540). The combination of Pem plus B has produced promising results in a phase II trial in recurrent or metastatic SCCHN (ASCO 2008; A6069). Upregulation of VEGF has been associated with E resistance, thus, adding B to the RT plus PemE regimen may enhance antitumor activity. Methods: Eligible patients have previously untreated stage III/IV SCCHN of the oropharynx, larynx or hypopharynx, ECOG performance status (PS) 0-1, no history of bleeding and not receiving therapeutic anticoagulation, and adequate laboratory parameters. Patients are randomized after stratification by stage, site, and PS to receive either: A) RT 2Gy/day to 70 Gy, E 250 mg/m2 weekly, after a loading dose of 400 mg/m2 1 week prior starting RT, and Pem 500 mg/m2 every 21 days × 3 cycles (PemE), or B) the same regimen plus B 15 mg/kg every 21 days × 3 cycles during RT (B-PemE) followed by B maintenance × 8 cycles (24 weeks). All patients receive folic acid and B12, and antibiotic prophylaxis with cycles 2 and 3. Placement of prophylactic gastrostomy tube is strongly recommended. The primary endpoint is the progression-free survival (PFS) at 2 years. We target a 2-year PFS of 64% assuming 46% as historical control. 40 patients will be accrued per arm. Secondary objectives include local PFS, distant PFS, overall survival, toxicities, and quality-of-life. 14 pts have been enrolled in this ongoing trial (6 in arm A; 8 in arm B). No significant financial relationships to disclose.
Language Error in Figure in: Effect of Long-Detection Interval vs Standard-Detection Interval for Implantable Cardioverter-Defibrillators on Antitachycardia Pacing and Shock Delivery: The Advance III Randomized Clinical Trial
Journal: JAMA (2013)

Effect of Long-Detection Interval vs Standard-Detection Interval for Implantable Cardioverter-Defibrillators on Antitachycardia Pacing and Shock Delivery: The ADVANCE III Randomized Clinical Trial